Abbott Laboratories 9MCY26 profit rises 25% to nearly Rs7bn

October 27, 2026 (MLN): Net profit rose 24.57% year-on-year to Rs6.68bn for the nine months ended September 30, 2026, from Rs5.37bn in the same period last year, as higher local sales, lower cost of sales and a bigger gross profit lifted Abbott Laboratories (Pakistan) Limited (PSX: ABOT).

Basic and diluted earnings per share (EPS) increased 24.58% to Rs68.28, compared with Rs54.81 a year earlier.

Net sales grew 4.32% to Rs58.66bn from Rs56.23bn. Local sales rose 5.99% to Rs57.14bn from Rs53.91bn, while export sales fell 34.40% to Rs1.52bn from Rs2.32bn.

Cost of sales edged down 1.20% to Rs36.44bn from Rs36.89bn. Gross profit climbed 14.86% to Rs22.21bn, up from Rs19.34bn.

Operating expenses, however, rose 6.25% to Rs10.76bn from Rs10.13bn. Selling and distribution expenses increased 6.36% to Rs9.04bn from Rs8.50bn, while administrative expenses grew 13.06% to Rs1.10bn from Rs972.48m. Other charges went up 8.54% to Rs1.36bn from Rs1.26bn.

Other income rose 23.65% to Rs745.997m from Rs603.34m, which helped offset part of the increase in expenses. Operating profit increased 24.32% to Rs11.45bn from Rs9.21bn.

Finance costs declined 6.46% to Rs51.79m from Rs55.36m. Profit before taxation rose 24.51% to Rs11.40bn from Rs9.16bn.

A minimum tax differential of Rs146.99m in the same period last year did not recur. Profit after this adjustment stood at Rs11.40bn, up 26.54% from Rs9.01bn.

The current tax charge for the year increased 16.36% to Rs4.46bn from Rs3.83bn, and a prior-year tax credit of Rs27.55m was recorded. Deferred tax swung to a charge of Rs290.75m from a credit of Rs183.23m a year earlier, leaving net profit at Rs6.68bn.

Copyright Mettis Link News